Clinical trial
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
NCT00354120 · Gruppo Italiano Trapianto di Midollo Osseo, Other · Completed
Key facts
| NCT number | NCT00354120 |
|---|---|
| Title | Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant |
| Official title | Randomized Study for Comparison of Reduced Intensity Conditioning Protocols Containing Either Thymoglobuline or Alemtuzumab in Patients Undergoing Allogeneic Transplant From Voluntary Unrelated Donors |
| Acronym | GLOBAL |
| Lead sponsor | Gruppo Italiano Trapianto di Midollo Osseo, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Acute Myeloblastic Leukemia, Lymphoblastic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia, Myelofibrosis, Lympho-proliferative Diseases |
| Intervention type | Drug |
| Interventions | Alentuzumab, Globulina antilinfocitaria |
| Enrollment | 121 |
| Start date | Mar 1, 2005 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Jul 20, 2006 |
| Last update posted | Mar 10, 2023 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: